First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Trial Profile

First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs CMX-521 (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 12 Jun 2018 According to a Chimerix media release, study results are expected to be reported in the second half of 2018.
    • 07 May 2018 According to a Chimerix media release, the company is completing the fourth cohort in the single ascending dose part of ti study and oral presentation will be presented at the International Conference on Antiviral Research (ICAR) in June 2018.
    • 05 Jan 2018 According to a Chimerix media release, study results are expected in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top